z-logo
open-access-imgOpen Access
Cell free DNA analysis by SiRe® next generation sequencing panel in non small cell lung cancer patients: focus on basal setting
Author(s) -
Pasquale Pisapia,
Francesco Pepe,
Riccardo Smeraglio,
Maria Russo,
Danilo Rocco,
Roberta Sgariglia,
Mariantonia Nacchio,
Caterina De Luca,
Elena Vigliar,
Claudio Bellevicine,
Giancarlo Troncone,
Umberto Malapelle
Publication year - 2017
Publication title -
journal of thoracic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 60
eISSN - 2077-6624
pISSN - 2072-1439
DOI - 10.21037/jtd.2017.06.97
Subject(s) - medicine , sire , oncology , lung cancer , basal (medicine) , dna sequencing , focus (optics) , cell free fetal dna , computational biology , dna , bioinformatics , genetics , biology , pregnancy , fetus , prenatal diagnosis , zoology , physics , insulin , optics
Non small cell lung cancer (NSCLC) is diagnosed in most cases on small tissue samples, such as cytological preparations and histological biopsies; these limited tissue specimens may be not always sufficient for testing epidermal growth factor receptor ( EGFR ) mutations and other relevant predictive biomarkers. Cell-free DNA (cfDNA) can be used as a surrogate for EGFR mutational testing, whenever tissue is unavailable. However, the detection of gene mutations on cfDNA is challenging; in fact, the extremely low concentration of circulating tumor DNA requires the implementation of highly sensitive and validated next generation techniques.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom